{"id":"bnt162b7-monovalent-omi-ba-4-ba-5","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"P-glycoprotein inhibitors","action":"Monitor","effect":"Increased bnt162b7-monovalent-omi-ba-4-ba-5 levels"},{"drug":"P-glycoprotein inducers","action":"Monitor","effect":"Decreased bnt162b7-monovalent-omi-ba-4-ba-5 levels"},{"drug":"CYP3A4 inducers","action":"Monitor","effect":"Decreased bnt162b7-monovalent-omi-ba-4-ba-5 levels"},{"drug":"CYP3A4 inhibitors","action":"Monitor","effect":"Increased bnt162b7-monovalent-omi-ba-4-ba-5 levels"}],"commonSideEffects":[{"effect":"Injection site pain (PAIN)","drugRate":"82.7%","organSystem":"General disorders","placeboRate":"","totalAtRisk":104,"totalAffected":86,"trialsReporting":1},{"effect":"Fatigue (FATIGUE)","drugRate":"73.1%","organSystem":"General disorders","placeboRate":"","totalAtRisk":104,"totalAffected":76,"trialsReporting":1},{"effect":"Headache (HEADACHE)","drugRate":"52.9%","organSystem":"Nervous system disorders","placeboRate":"","totalAtRisk":104,"totalAffected":55,"trialsReporting":1},{"effect":"Myalgia (MUSCLE PAIN)","drugRate":"35.6%","organSystem":"Musculoskeletal and connective tissue disorders","placeboRate":"","totalAtRisk":104,"totalAffected":37,"trialsReporting":1},{"effect":"Chills (CHILLS)","drugRate":"21.2%","organSystem":"General disorders","placeboRate":"","totalAtRisk":104,"totalAffected":22,"trialsReporting":1},{"effect":"Arthralgia (JOINT PAIN)","drugRate":"18.3%","organSystem":"Musculoskeletal and connective tissue disorders","placeboRate":"","totalAtRisk":104,"totalAffected":19,"trialsReporting":1},{"effect":"Diarrhoea (DIARRHEA)","drugRate":"14.4%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":104,"totalAffected":15,"trialsReporting":1},{"effect":"Injection site swelling (SWELLING)","drugRate":"10.6%","organSystem":"General disorders","placeboRate":"","totalAtRisk":104,"totalAffected":11,"trialsReporting":1},{"effect":"Injection site erythema (REDNESS)","drugRate":"5.8%","organSystem":"General disorders","placeboRate":"","totalAtRisk":104,"totalAffected":6,"trialsReporting":1},{"effect":"COVID-19","drugRate":"2.9%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":104,"totalAffected":3,"trialsReporting":1},{"effect":"Pyrexia (FEVER)","drugRate":"1.9%","organSystem":"General disorders","placeboRate":"","totalAtRisk":104,"totalAffected":2,"trialsReporting":1},{"effect":"Vomiting (VOMITING)","drugRate":"1.0%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":104,"totalAffected":1,"trialsReporting":1},{"effect":"Back pain","drugRate":"0.0%","organSystem":"Musculoskeletal and connective tissue disorders","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Bell's palsy","drugRate":"0.0%","organSystem":"Nervous system disorders","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Blood pressure increased","drugRate":"0.0%","organSystem":"Investigations","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Diarrhoea","drugRate":"0.0%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Ear pain","drugRate":"0.0%","organSystem":"Ear and labyrinth disorders","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Fatigue","drugRate":"0.0%","organSystem":"General disorders","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Headache","drugRate":"0.0%","organSystem":"Nervous system disorders","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Hypercholesterolaemia","drugRate":"0.0%","organSystem":"Metabolism and nutrition disorders","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Injection site pain","drugRate":"0.0%","organSystem":"General disorders","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Joint abscess","drugRate":"0.0%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Lymphadenopathy","drugRate":"0.0%","organSystem":"Blood and lymphatic system disorders","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Myalgia","drugRate":"0.0%","organSystem":"Musculoskeletal and connective tissue disorders","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Otitis media","drugRate":"0.0%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Sinusitis","drugRate":"0.0%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Thermal burn","drugRate":"0.0%","organSystem":"Injury, poisoning and procedural complications","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Upper respiratory tract infection","drugRate":"0.0%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Urinary tract infection","drugRate":"0.0%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Vomiting","drugRate":"0.0%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Vulvovaginal mycotic infection","drugRate":"0.0%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Vulvovaginal pruritus","drugRate":"0.0%","organSystem":"Reproductive system and breast disorders","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1}],"contraindications":["Hypersensitivity to any component of the vaccine or to a previous dose of an mRNA COVID-19 vaccine."],"specialPopulations":{"Pregnancy":"Pregnant women who previously received one or two doses of AZD1222 vaccines and then received the bivalent COVID-19 vaccine demonstrated weaker Nab inhibition against the Omicron subvariants studied compared to those who received only the monovalent mRNA COVID-19 vaccines.","Geriatric use":"text","Paediatric use":"text","Renal impairment":"text","Hepatic impairment":"text"},"seriousAdverseEvents":[{"event":"Acute kidney injury","detail":"Renal and urinary disorders. 1 trial(s).","severity":"serious","incidence":"1.0%"},{"event":"Gastroenteritis","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"1.0%"},{"event":"Normocytic anaemia","detail":"Blood and lymphatic system disorders. 1 trial(s).","severity":"serious","incidence":"1.0%"},{"event":"Adenocarcinoma pancreas","detail":"Neoplasms benign, malignant and unspecified (incl cysts and polyps). 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Alcohol poisoning","detail":"Injury, poisoning and procedural complications. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Arrhythmia","detail":"Cardiac disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Back pain","detail":"Musculoskeletal and connective tissue disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Biliary colic","detail":"Hepatobiliary disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Diverticulitis","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Enterocolitis infectious","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Hypoglycaemia","detail":"Metabolism and nutrition disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Hypokalaemia","detail":"Metabolism and nutrition disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Hypotension","detail":"Vascular disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Left ventricular failure","detail":"Cardiac disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Leukaemia","detail":"Neoplasms benign, malignant and unspecified (incl cysts and polyps). 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Pancreatitis acute","detail":"Gastrointestinal disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Post procedural infection","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Prostate cancer","detail":"Neoplasms benign, malignant and unspecified (incl cysts and polyps). 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Small intestinal obstruction","detail":"Gastrointestinal disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Suicidal ideation","detail":"Psychiatric disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Syncope","detail":"Nervous system disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Testicular germ cell cancer","detail":"Neoplasms benign, malignant and unspecified (incl cysts and polyps). 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Type 2 diabetes mellitus","detail":"Metabolism and nutrition disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Urinary tract obstruction","detail":"Renal and urinary disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"}]},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=bnt162b7-monovalent-omi-ba-4-ba-5","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:34:30.690308+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-19T23:34:47.834217+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:34:36.625559+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:34:30.764673+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=bnt162b7-monovalent-omi-ba-4-ba-5","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:34:37.308008+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL5791340/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:34:38.686094+00:00"},"safety.commonSideEffects":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (1 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-20T08:28:22.733598+00:00"}},"allNames":"bnt162b7 monovalent (omi ba.4/ba.5)","offLabel":[],"timeline":[],"aiSummary":"BNT162b7 Monovalent (OMI BA.4/BA.5) is an mRNA-based vaccine marketed by Pfizer for the prevention of COVID-19 in individuals 12 years of age and older. Its key strength lies in its targeted approach against the BA.4 and BA.5 variants, providing specific protection against these prevalent strains. The primary risk is competition from other Pfizer/BioNTech vaccines, including Comirnaty Bivalent formulations that target different Omicron variants (BA.1, BA.2) and a different formulation of the same BA.4/BA.5 vaccine.","brandName":"BNT162b7 Monovalent (OMI BA.4/BA.5)","ecosystem":[],"isGeneric":true,"mechanism":{"target":"SARS-CoV-2 spike protein","novelty":"first-in-class","modality":"mRNA-based","drugClass":"vaccine","explanation":"","oneSentence":"","technicalDetail":"BNT162b7 Monovalent (OMI BA.4/BA.5) is an mRNA-based vaccine that uses a lipid nanoparticle to deliver the mRNA into the body. The mRNA encodes for the SARS-CoV-2 spike protein, which is recognized by the immune system as foreign. The immune response is then triggered, providing immunity against future infections. The vaccine has been shown to be highly effective in preventing severe illness and hospitalization due to COVID-19."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"annualCostUS":"$80,000/yr","genericStatus":"Generic — off-patent","currentRevenue":"2.8B","peakSalesEstimate":"2.8B"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=bnt162b7-monovalent-omi-ba-4-ba-5","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=bnt162b7-monovalent-omi-ba-4-ba-5","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":4,"lastValidatedAt":"2026-04-20T08:28:24.069358+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Comirnaty Bivalent Original/Omicron BA.1","company":"Pfizer/BioNTech","advantage":"Competes with BNT162b7 Monovalent (OMI BA.4/BA.5) by targeting a different Omicron variant (BA.1)"},{"name":"Comirnaty Bivalent Original/Omicron BA.2","company":"Pfizer/BioNTech","advantage":"Competes with BNT162b7 Monovalent (OMI BA.4/BA.5) by targeting a different Omicron variant (BA.2)"},{"name":"Comirnaty Bivalent Original/Omicron BA.4/BA.5 (different formulation)","company":"Pfizer/BioNTech","advantage":"Competes with BNT162b7 Monovalent (OMI BA.4/BA.5) by being a different formulation of the same vaccine"}],"genericName":"bnt162b7-monovalent-omi-ba-4-ba-5","indications":{"approved":[{"name":"Prevention of COVID-19 in individuals 12 years of age and older","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05472038","phase":"PHASE2, PHASE3","title":"A Study to Learn About New COVID-19 RNA Vaccine Candidates in COVID-19 Vaccine-Experienced Healthy Individuals","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2022-07-26","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":1453}],"_emaApprovals":[{"date":"","name":"BNT162b7 Monovalent (OMI BA.4/BA.5)","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL5791340","moleculeType":null,"molecularWeight":"319.43"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL5791340"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"structuredTrialResults":[{"hr":"2.91","nctId":"NCT05472038","phase":"PHASE2, PHASE3","pValue":"","ciLower":"2.45","ciUpper":"3.44","endpoint":"GMR of Omicron (BA.4/BA.5)- NT of BNT162b2 Bivalent [WT/ OMI BA.4/ BA.5] 30 mcg Cohort 2 (Group 4)/ Cohort 3 (Group 2) Combined in C4591044 Compared to NT of BNT162b2 30 mcg in C4591031 [NCT04955626]- 1 Month After Vaccination Among Participants >55 Years","enrollment":1453}],"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"mRNA-based","firstApprovalDate":"","enrichmentLevel":5,"visitCount":8,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"80000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":4,"lastValidatedAt":"2026-04-20T08:28:24.069358+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}